<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43504">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01854125</url>
  </required_header>
  <id_info>
    <org_study_id>NanjingPLAGH1</org_study_id>
    <secondary_id>Jinling 01</secondary_id>
    <nct_id>NCT01854125</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites</brief_title>
  <official_title>Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in
      liver cirrhosis patients with refractory ascites are very wretched. The objective of this
      study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem
      cells (BMSCs) transplantation via liver artery in Child-Pugh B and C stage of liver
      cirrhosis patients with refractory ascites. The immunomodulatory impact of MSCs in fibrosis
      was confirmed, and several clinical studies have applied MSCs to eliminate the progression
      of fibrosis. In this research the investigators will study the affect and influence of MSCs
      in the patients,include assay of liver function,variation of ascites,Child-Pugh score etc.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in immune function,liver function in blood</measure>
    <time_frame>before and one to 12 weeks after therapy</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Function in Blood</condition>
  <condition>Liver Function in Blood</condition>
  <condition>Variation of Ascites</condition>
  <condition>Characters of Quality of Life</condition>
  <condition>Child-Pugh Score</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every patient is given 1x106 MSCs per kg infused via liver artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stem cells transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mesenchymal stem cells transplantation</intervention_name>
    <description>Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.</description>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>stem cells transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow msenchymal stem cells transplantation</intervention_name>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>stem cells transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria:

        Aged 18~65 years. Ultrasonographic evidences of cirrhosis. hepatic cirrhosis patients with
        refractory ascite.

        Exclusion Criteria:

        history of moderate to severe hepatic encephalopathy or variceal bleeding during the last
        two months before enrolment.

        Prothrombin time is less than 30s. Severe problems in other vital organs(e.g.the
        heart,renal or lungs). Liver tumor on ultrasonography, CT or MRI examination. Pregnant or
        lactating women. Imaging evidences of vascular thromboses.

        -

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fangyu Wang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fangyu Wang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kharaziha P, Hellstr√∂m PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205.</citation>
    <PMID>19455046</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 14, 2013</lastchanged_date>
  <firstreceived_date>May 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Shihui</investigator_full_name>
    <investigator_title>Department of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>immun function</keyword>
  <keyword>liver function</keyword>
  <keyword>ascites</keyword>
  <keyword>quality of life</keyword>
  <keyword>Child-Pugh score</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
